{"id":72487,"date":"2023-06-30T17:20:19","date_gmt":"2023-06-30T15:20:19","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=72487"},"modified":"2023-06-30T17:50:16","modified_gmt":"2023-06-30T15:50:16","slug":"novartis-cede-attivita-oftalmologica-front-of-eye-a-bausch-lomb","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/novartis-cede-attivita-oftalmologica-front-of-eye-a-bausch-lomb\/","title":{"rendered":"Novartis sells \u201cfront of eye\u201d ophthalmology business to Bausch + Lomb"},"content":{"rendered":"

Novartis sells ophthalmology assets to Bausch + Lomb for $2.5 billion<\/h2>\n

Novartis, a Swiss multinational operating in the pharmaceutical sector, has signed a\u00a0agreement for \"\"divestment of the ophthalmology business<\/strong>\u00a0front of eye to Bausch + Lomb, a North American eye health company, in a transaction valued at up to $2.5 billion, including $1.75 billion in cash upfront.<\/p>\n

The deal also includes\u00a0Xiidra<\/strong><\/a>, the first approved prescription treatment for the signs and symptoms of dry eye disease, the investigational drug SAF312 (libvatrep<\/strong>), under development as a therapy for chronic ocular surface pain (COSP), and other assets.<\/p>\n

"Our\u00a0continuous improvement of the portfolio<\/strong>\u00a0it allows us to best employ our scientific expertise and resources towards priority therapeutic programs and areas, while remaining open to opportunistic development for additional high-impact conditions, leveraging our advanced technology platforms,\u201d he said\u00a0Ronny Gal, Novartis Chief Strategy & Growth Officer<\/strong>.<\/p>\n

The acquisition \u201cprovides the\u00a0scale needed<\/strong>\u00a0for the company and transform our pharmaceutical business to make us a leader in ocular surface diseases,\u201d he said\u00a0Brent Saunders, CEO of Bausch + Lomb<\/strong>. \u201cThe deal is also expected to accelerate margin expansion through a broader mix of pharmaceuticals in our portfolio, deliver strong and immediate earnings lift, and present a clear path to deleveraging,\u201d he added.<\/p>\n

Under the terms of the agreement, Novartis will receive payments of up to $750 million related to anticipated future sales of Xiidra, SAF312 (libvatrep), and OJL332. The closing is expected in\u00a0second half of 2023<\/strong>.<\/p>\n

(TELEBORSA) 06-30-2023\u00a0<\/a><\/p>\n

Novartis press release. Novartis signs agreement to divest 'front of eye' ophthalmology assets in line with focused strategy<\/span><\/a><\/p>\n

Bausch + Lomb Will Acquire XIIDRA\u00ae<\/a><\/p>\n

Related news: Novartis acquires the American Chinook for 3.2 billion dollars<\/a><\/p>\n

AIFA. FDA approves treatment for dry eye syndrome<\/a><\/p>\n

9 main courses and acquisitions in the 1st semester of 2023 in the pharmaceutical industry<\/a><\/p>\n

 <\/p>\n

\"\"Note:<\/p>\n

The story begins in 1853 when John Jacob Bausch borrowed a 60$ from his friend Henry Lomb to open a small optical shop.<\/p>\n

In Rochester, New York, thanks to \u00abSixty dollars and a handshake\u00bb opens \u201cJ. Bausch Optician\u201d. That handshake remains the only contract the two ever entered into.<\/p>\n

170 years later Bausch + Lomb is a world leader in eye health.
\nIn 2013 Bausch + Lomb was acquired by the international group Valeant Pharmaceuticals Inc., a multinational pharmaceutical company that has 22,000 employees and is present in more than 150 countries worldwide.<\/p>","protected":false},"excerpt":{"rendered":"

Novartis cede asset oftalmologia a Bausch + Lomb per 2,5 miliardi di dollari Novartis, multinazionale svizzera che opera nel settore farmaceutico, ha firmato un\u00a0accordo per la cessione delle attivit\u00e0 di oftalmologia\u00a0“front of eye” a\u00a0Bausch + Lomb, azienda nordamericana attiva nel campo della salute degli occhi, in una transazione del valore massimo di 2,5 miliardi di …<\/p>","protected":false},"author":4,"featured_media":66815,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-72487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/72487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=72487"}],"version-history":[{"count":9,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/72487\/revisions"}],"predecessor-version":[{"id":72498,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/72487\/revisions\/72498"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/66815"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=72487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=72487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=72487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}